



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Trust issues in vaccine uptake

George Williams, MD, FASA, FCCM, FCCP

UT Health McGovern Medical School at Houston, Department of Anesthesiology, 6431 Fannin St, MSB 5.020, Houston, TX 77030, United States



Three major vaccines for the prevention of novel 2019 coronavirus (COVID-19) have been approved for administration to patients in the United States via emergency use authorization [1–3]. These include two mRNA based vaccines, commonly known as the Pfizer (BNT162b2) and Moderna (mRNA-1273) vaccines along with the adenovirus vector based Janssen (Ad26.COV2-S) vaccines. The studies which evaluated the efficacy and safety of these vaccinations were conducted using patient populations of no fewer than 19,000 patients representing all major ethnic and racial groups from across the US. Additionally, enrollment in and progress of the vaccine studies was highly publicized. Despite this attempted demographic balance and the recent FDA approval of the Pfizer vaccine, there remains substantial hesitancy to receiving a COVID-19 vaccine throughout the US population. This hesitancy persists despite concerns about the ability of the US health care system to care for ‘surges’ of patients who are hospitalized due to acute COVID-19 pneumonia.

There are multiple causes for this lack of facility capacity which results from lack of physical or human infrastructure such ICU beds or clinical staff, but also commonly required and crucial items such as medications and disposable equipment. Supply chain systems both within the US and internationally have demonstrated substantial fragility in the manufacturing of chemicals and pharmaceuticals with resulting disruptions manifested during the COVID-19 pandemic [4]. Crisis standards of care have had to be implemented in various jurisdictions during the pandemic [5]. Additionally, surges in COVID-19 cases not only reduces treatment capacity for those infected with COVID-19, but have been shown to effect the mortality of patients who do not have a COVID-19 yet require hospitalization for another reason [6]. Prevention of COVID-19 infection with vaccination and pathogen hygiene appear to be the primary means to minimize the clinical burden of COVID-19 infection.

The World Health Organization has declared vaccine hesitancy a “major threat” to global health [7]. It is important to note that vaccine hesitancy is not unique to the new COVID-19 vaccines and in fact has been an ongoing concern for many years. The proliferation of social media, a medium which permits the immediate dissemination of uneditorialized content to a worldwide audience, has been credited with facilitating and sustaining the ‘anti-vaccine’ movement. In the US, political party affiliation, preferred sources of news and underlying state of health have been demonstrated to correlate with the likelihood of intent to be vaccinated for COVID-19 [8]. Additionally, conspiracy

theories pertaining to makeup and intention of the COVID-19 vaccines as well as the origins of the COVID-19 virus itself abound [9].

Cited as an effort to protect both patients and health care professionals, multiple health care facilities have begun requiring vaccination as a condition of employment, even though the Food and Drug Administration (FDA) has only granted an Emergency Use Authorization (EUA) for the Moderna and Janssen vaccines mentioned above [10]. The issuance of the EUA does not imply less diligence on the part of the FDA, but the long-term outcome studies commensurate to a traditional full FDA authorization have not been practically possible given the scope of the COVID-19 pandemic. While many facilities are allowing religious or health related exemptions, most hospital employees will have to either agree to be vaccinated or face termination of employment. Examples where this could be particularly challenging include pregnant women or members of historically marginalized minority communities which have a pre-existing distrust of the health care system. Nonetheless, transmission of COVID-19 from hospital employees to patients is known to occur and vaccination is an important tool to minimize this potential transmission, though transmission of COVID-19 by vaccinated individuals albeit as a much lower frequency [11]. An analogous approach has been taken for the influenza vaccine for many years, though it is fully FDA approved for use in the US. The power of the example of health care practitioners may play role in public acceptance of any of the COVID-19 vaccines; the fact that in some practices and countries, many healthcare team members are unwilling to get vaccinated may further stoke fears in the general population [12].

As multiple variants have emerged increasing the infectivity and immunogenicity of COVID-19 infection, the ramifications of any societal disparities in vaccine adoption are likely to become more pronounced. Potentially, the most effective mechanism to overcome misinformation obtained from rogue news, social media platforms, and antivaccination associates may be personal interactions with trusted friends and neighbors. Additionally, more intentional inclusion of individuals of multiple ethnic, cultural, and political backgrounds may allow penetration into subsections of society less inclined to be vaccinated. Clearly, setting realistic expectations about the potential protective effects of vaccination is also important, as any medical predictions of future COVID-19 trends that do not turn out to be accurate can serve to dissuade confidence in the US public health apparatus. Even with data supporting the administration of COVID-19 vaccines, well informed individuals may have an understandable hesitancy to receiving a vaccine product that has been so rapidly developed and deployed. Indeed, fear in general or various clinical scenarios such as pregnancy, previous negative experience

E-mail address: George.W.Williams@uth.tmc.edu.

with other vaccinations and additional factors may result in an intractable resistance to considering vaccination. In such instances, regular testing should be offered whenever logistically feasible while maintaining patient safety. Finally, it is important for the medical community to prepare to accept the significant possibility that a significant portion of the population may never consent to being vaccinated; therefore, modeling of future public health plans should take that reality into account.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author statement

The author declares that he (George Williams, MD, FASA, FCCM, FCCP) solely produced the original draft and edited draft of this manuscript in its entirety. No external funding was used to produce this manuscript.

References

- [1] Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. *N Engl J Med*. 2021;384(23):2187–201.
- [2] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403–16.
- [3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383(27):2603–15.
- [4] Gomez M, Garcia S, Rajtmajer S, Grady C, Mejia A. Fragility of a multilayer network of intranational supply chains. *Appl Netw Sci*. 2020;5(1):71.
- [5] Powell T, Chuang E. COVID in NYC: what we could do better. *Am J Bioeth*. 2020;20(7):62–6.
- [6] Sabbatini AK, Robicsek A, Chiu ST, Gluckman TJ. Excess mortality among patients hospitalized during the COVID-19 pandemic. *J Hosp Med*. 2021:E1–8.
- [7] Puri N, Coomes EA, Haghbayan H, Gunaratne K. Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases. *Hum Vaccin Immunother*. 2020;16(11):2586–93.
- [8] Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: results of a nationwide survey. *Vaccine*. 2021;39(7):1080–6.
- [9] Romer D, Jamieson KH. Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S. *Soc Sci Med*. 2020;263:113356.
- [10] Centor RM, Klompas M, Pearson M, Morris C. Annals on call - the case for mandating COVID-19 vaccines for health care workers. *Ann Intern Med*. 2021:OC1.
- [11] Teran RA, Walblay KA, Shane EL, Xydis S, Gretsches S, Gagner A, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-march 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(17):632–8.
- [12] Pataka A, Kotoulas S, Stefanidou E, Grigoriou I, Tzinas A, Tsiouprou I, et al. Acceptability of Healthcare Professionals to Get Vaccinated against COVID-19 Two Weeks before Initiation of National Vaccination. *Medicina (Kaunas)*. 2021;57(6).